Andrew M. Evens

机构：Rutgers Cancer Institute · ORCID：0000-0002-6900-1824

发表论文 659 篇 · 总被引 18141 次 · h-index 67

代表论文

• Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826 (2025 · Journal of Clinical Oncology · 被引 28)
• Circulating tumor DNA analyses of molecular tumor burden are superior to PET-assessed responses in patients with advanced stage classic Hodgkin lymphoma treated on SWOG S1826 (2025 · Blood · 被引 9)
• The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool (2025 · Blood Advances · 被引 9)
• Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826 (2026 · Journal of Clinical Oncology · 被引 7)
• Interim and end-of-treatment FDG-PET demonstrate limited ability to predict 3-year progression-free survival with nivolumab-AVD in first-line treatment of advanced stage Hodgkin lymphoma: Imaging sub-analysis of Phase 3 S1826 study (2025 · Blood · 被引 7)
• An Individualized Prediction Model for Early-Stage Classic Hodgkin’s Lymphoma (2025 · NEJM Evidence · 被引 4)